Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Ceritinib in ALK+ NSCLC
NCT02292550Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of ribociclib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Novartis. Primary endpoints: Incidence rate of dose limiting toxicities at 1 month, Overall Response Rate up to 24 months and 1 more. Started May 2015; status: completed.
02
Drugs
ribociclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02292550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292550.